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Background
Current anti-malarial drugs have been selected on the
basis of their activity against the symptom-causing asex-
ual blood stage of the parasite. How many of these drugs
also target gametocytes, the sexual stage responsible for
disease transmission, remains unknown. Blocking trans-
mission is one of the main strategies in the eradication
agenda and implies the identification of new molecules
active against gametocytes. However, so far, the main
limitation for measuring the effect of molecules against
mature gametocytes on a large scale is the lack of a stan-
dardized and reliable method. Here we provide an effi-
cient method to produce and purify mature gametocytes
in vitro. Based on this new procedure, we developed a
robust, affordable and sensitive ATP bioluminescence-
based assay. We then assessed the activity of 17 gold-
standard anti-malarial drugs on Plasmodium late stage
gametocytes.
Materials and methods
Difficulties in producing large amounts of gametocytes
have limited progress in the development of malaria trans-
mission blocking assays. We improved the method estab-
lished by Ifediba and Vanderberg to obtain viable, mature
gametocytes en masse. We designed an assay to determine
the activity of antimalarial drugs based on the intracellular
ATP content of purified stage IV-V gametocytes after 48h
of drug exposure in 96/384-well microplates. Measure-
ment of drug activity on asexual stages and cytotoxicity on
HepG2 cells were also obtained to estimate the specificity
of the active drugs. The methodology is fully described at
Lelièvre et a l[1].
Results
The assay was validated by comparing traditional micro-
scopy examination with the ATP bioluminescence assay
using a set of 6 anti-plasmodial drugs. We obtained
comparable IC50 values with both methods.
After validation, 16 clinically relevant antimalarial drugs
presenting different mechanism of action were tested.
Only epoxomicin (0.42 nM) and methylen blue (0.49 µM)
showed IC50 values in the range of nanomolar.
Epoxomicin is an inhibitor of proteasome activity,
exerting a toxic effect on the parasite, but as this function
is also essential in mammalian cells its cytotoxicity is of
concern.
Primaquine has been reported to destroy the inner
structure of P.falciparum mitochondria. It is assumed
that primaquine activity depends on the formation of
metabolites, more active than the parent compound.
This 8-aminoquinoline has long been known to reduce
the prevalence of circulating gametocytes in the periph-
eral bloodstream of patients. Due to the absence of the
active metabolites involved in its mechanism of action,
primaquine remains inactive in vitro (20.9 µM). Methy-
lene blue (MB) was identified as a specific inhibitor of
P. falciparum glutathione reductase, blocking heme
polymerization within the food vacuole. Our study eval-
uated for the first time the IC50 of MB on stage IV-V
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gametocytes and HepG2 cell line (6.52 µM), founding a
good activity but quite high cytotoxicity.
Conclusions
The work described represents another significant step [2]
towards determination of activity of new molecules on
mature gametocytes with an automated assay suitable for
medium/high-throughput screening. Considering that the
biology of the sexual stages is very different from asexual
forms, screening of compound libraries would allow us to
discover novel anti-malarial drugs to target gametocyte-
specific metabolic pathways.
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